Skip to main content
An official website of the United States government

imlunestrant

An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, imlunestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.
Synonym:SERD LY3484356
Code name:LY 3484356
LY-3484356
LY3484356
Search NCI's Drug Dictionary